<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023345</url>
  </required_header>
  <id_info>
    <org_study_id>P160301</org_study_id>
    <nct_id>NCT03023345</nct_id>
  </id_info>
  <brief_title>Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer</brief_title>
  <acronym>FOSTINE</acronym>
  <official_title>Evaluation of the Feasibility and Tolerance of Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if trans-rectal microwave ablation of the index
      tumor of patients with low-risk prostate cancer is sufficiently precise and safe, using
      MRI-transrectal ultrasound image registration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In men with low-risk prostate cancer, European and American guidelines recommend either
      active surveillance or whole-gland treatments, with significant induced morbidity and burden
      on quality of life. Focal treatments of the index tumor are currently under investigation to
      decrease morbidity while proposing active treatment.

      The purpose of this study is to determine the feasibility, precision and safety of a novel
      ablation treatment using microwaves, delivered transrectally under real-time guidance with
      MRI-transrectal ultrasound image registration. The index tumor will be detected with prostate
      MRI and characterized with targeted biopsies using MRI-transrectal ultrasound image
      registration. It will then be ablated with microwaves using the same transrectal approach and
      guidance system (KOELIS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete necrosis of the index tumor on prostate MRI</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Margins of necrosis around the index tumor on prostate MRI</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>7 days</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and Ejaculatory function using the International Index Erectile Function (IIEF) self questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>to assess sexual tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>7 days</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>1 month</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>3 months</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms using IPSS</measure>
    <time_frame>6 months</time_frame>
    <description>to assess urinary tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cancer on targeted biopsies within the treated volume</measure>
    <time_frame>6 months</time_frame>
    <description>to assess oncological efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Low-Risk Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Microwave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave trans rectal focal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave trans rectal focal treatment</intervention_name>
    <description>Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration</description>
    <arm_group_label>Microwave</arm_group_label>
    <other_name>Microwave thermal ablation system called TATO (Biomedical)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 45 to 76 years old ;

          -  Life expectancy above 10 years ;

          -  Diagnosis of prostate cancer confirmed on prostate biopsies ;

          -  Low risk of progression, defined with D'Amico criteria :

               -  T1c or T2a stage

               -  Maximum Gleason score of 3+3, including targeted biopsies

               -  Prostate Specific Antigen &lt;10 ng/mL

          -  Detection of the index tumor with prostate MRI, characterized with targeted biopsies
             using MRI-transrectal ultrasound image registration ;

          -  Patient accepting to be followed after the procedure using active surveillance
             protocol standards ;

          -  Patient affiliated to national health care insurance ;

          -  Free consent, informed and written, dated and signed by the patient and the
             investigator before enrollment.

        Exclusion Criteria:

          -  Medical past history of prostatic surgery ;

          -  Medical past history of radiotherapy or pelvic trauma ;

          -  Medical past history of acute or chronic prostatitis

          -  severe BPH-related urinary tract symptoms defined as an IPSS &gt;18 ;

          -  Extra-capsular extension or seminal vesicle invasion on prostate MRI.

          -  Tumor involvement &gt; 3 mm on systematic biopsies outside the tumor volume detected on
             MRI.

          -  Tumor largest axis &gt; 20 mm on prostate MRI ;

          -  Distance of less than 5 mm between the tumor and the rectum

          -  Patient unable to understand the course of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas BARRY DELONGCHAMPS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas BARRY DELONGCHAMPS, MD,PhD</last_name>
    <phone>+ 33 1 58 41 27 52</phone>
    <email>nicolas.barry-delongchamps@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clotilde SIMON, PhD</last_name>
    <phone>+33 1 58 41 11 90</phone>
    <email>clotilde.simon@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - H么pitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Barry Delongchamps, MD,PhD</last_name>
      <phone>+ 33 1 58 41 27 52</phone>
      <email>nicolas.barry-delongchamps@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>prostate</keyword>
  <keyword>PSA</keyword>
  <keyword>biopsies</keyword>
  <keyword>microwave trans rectal focal treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

